

**May 26, 2025**

National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai-400051

BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

**Ref: (i) Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
**(ii) SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

**Sub: Investors Presentation- Quarter IV and Financial Year ended March 31, 2025 – Orchid Pharma Limited ("the Company")**

Dear Sir/Madam,

With reference to the captioned subject and pursuant to Regulation 30, Sub- Para 15 of Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and in continuation to our earlier intimation, dated May 20, 2025, regarding the Analysts/Investors Earning Call scheduled to be held on May 26, 2025 at 04:30 P.M. (IST), please find enclosed Investors Presentation, inter-alia, including the financial performance of the Company for the Quarter-IV and Financial Year ended March 31, 2025.

The Investor Presentation is also made available on the website of the Company at [https://www.orchidpharma.com/invr\\_conferencecalls.html](https://www.orchidpharma.com/invr_conferencecalls.html)

You are requested to take the above intimation on record.

Thanking You,  
For **Orchid Pharma Limited**

**Kapil Dayya**  
**Company Secretary & Compliance Officer**  
**Mem. No.- F10698**

*Encl. as above*

# Orchid Pharma Limited

## Financials Q4 & FY-25

- All results in Standalone basis.
- These are approx. nos. for exact nos. pls refer financials.

# Financial Highlights

QTR-4

FY-25



**TOP LINE**

+9%

+13%

**EBIDTA**

-2%

+11%

**PBT**

-7%

+15%


**PAT**

-15%


+12%



## Turnover (Amt. in Cr.)




## EBITDA, PBT & PAT as % to Sales FY-25




# P&L Analysis – Gross Margin % to Sales

Gross Margin Yearly Basis



## P&L Analysis – Exp. % to Sales 12M



Thank You